ArticlePest management science2025
Proteolytic stabilization of a spider venom peptide results in an orally active bioinsecticide.
Article in Pest management science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- CED4 and CED4-like Peptides as Effective Plant Parasitic Nematicides.Molecules (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe toxin peptide U1-AGTX-Ta1b from the Hobo spider, Eratigena agrestis (Walckenaer, 1802), was studied to determine its potential to serve as a bioinsecticide.
resultsU1-AGTX-Ta1b has insecticidal potencies similar to commercial insecticides when injected directly into insect hemolymph but lacks activity when ingested by lepidopterans due to trypsin-like gut proteases. Alanine scanning identified an arginine and lysine rich patch on the peptide's surface that is critical for bioactivity. Targeted stability studies on these basic residues identified a single site, R9, to be the rate limiting site in U1-AGTX-Ta1b proteolysis. Mutation of position R9 to glutamine was sufficient to stabilize the peptide and render the toxin orally active with the additional benefit of enhanced temperature stability. Further refinement of the peptide to remove an O-linked glycosylation site and prevent exoprotease activity during expression in yeast led to a final peptide sequence suitable for commercialization as a bioinsecticide. This peptide displayed activity comparable to commercial insecticides in a range of crop/pest combinations.
conclusionA novel, peptide-based bioinsecticide derived from spider venom was developed to be stable and active by ingestion by lepidopteran pests. The peptide, U1-AGTX-Ta1b-QA, can replace or reduce the use of chemical insecticides and has been approved by the United States Environmental Protection Agency. © 2025 The Author(s). Pest Management Science published by John Wiley & Sons Ltd on behalf of Society of Chemical Industry.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.